Everything you need to know about Ozempic, Wegovy, Saxenda, and Mounjaro: Weight loss jabs and their effectiveness, availability, and risks.

Weight loss jabs have been making headlines recently, with success stories of people shedding pounds with the help of drugs like Ozempic, Wegovy, Saxenda, and Mounjaro. These drugs have been proven to be effective in aiding weight loss by suppressing appetite and helping individuals eat fewer calories.

In March 2023, the NHS announced that Wegovy, a drug containing semaglutide, would be available on prescription to obese individuals. This drug, which helped a third of people reduce their weight by 20% in trials, is now available from pharmacies like Boots. Semaglutide, the active drug in Wegovy, was originally sold as Ozempic for diabetes patients but was found to aid in weight loss as well.

Saxenda, another weight loss drug, is also available on Tier 3 and Tier 4 weight management services, where individuals are referred to weight management clinics led by experts. These drugs are not prescribed by GPs alone and must be taken as part of an overall weight loss program.

However, the supply of Wegovy on the NHS has been postponed indefinitely due to a surge in worldwide demand. Despite their effectiveness, these drugs come with side effects such as gut issues, pancreatitis, altered taste, kidney problems, and allergic reactions.

In early 2024, Mounjaro (tirzepatide) entered the market as another weight loss option. This drug, similar to Wegovy and Saxenda, has shown to be more effective in helping individuals lose weight. Mounjaro works by activating hormonal receptors that enhance insulin production, improve insulin sensitivity, and decrease food intake.

Overall, these weight loss jabs offer a promising solution for individuals struggling with obesity, but it is important to consult with healthcare professionals before starting any weight loss medication.